The short version of GLP-1 analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-10. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
== Life and education == Christian Hackenberger grew up in Damme. He attended the Gymnasium Damme, where he obtained his Abitur in 1995. After completing his civil service, he studied chemistry at the Albert-Ludwigs-Universität in Freiburg (1996–1998) and the University of Wisconsin-Madison (M.S. with Samuel H. Gellman, 1998–1999), with support from the German Academic Scholarship Foundation. He pursued his doctoral studies at the RTWH Aachen (2000–2003), where he worked under Prof. Carsten Bolm as a Kekulé Fellow from the Fonds der Chemischen Industrie. During this time, he also worked as an editorial assistant in scientific journalism for the WDR broadcast "Quarks & Co". From 2003 to 2005 he was a DAAD Postdoctoral Fellow at the Massachusetts Institute of Technology under Prof. Barbara Imperiali. In 2005, Hackenberger founded his own research group at the Free University of Berlin in 2005 as an Emmy Noether Fellow. In 2011, he was appointed as W2 Professor of Bioorganic Chemistry at the Free University of Berlin as the first Plus 3 awardee from the Boehringer Ingelheim Foundation. In 2012, he became Leibniz-Humboldt Professor for Chemical Biology at the Leibniz Research Institute for Molecular Pharmacology and the Humboldt University of Berlin. In 2020, Hackenberger co-founded the Munich-based biotechnology company Tubulis, which specializes in developing antibody-drug conjugates. He has served as associate editor of the Royal Society of Chemistry's scientific journals Organic and Biomolecular Chemistry (2015–2023) and Chemical Science (since 2024).
Graves' disease is an autoimmune disorder that is the most common cause of hyperthyroidism. In Graves' disease, for an unknown reason autoantibodies develop against the thyroid stimulating hormone receptor. These antibodies activate the receptor, leading to development of a goitre and symptoms of hyperthyroidism, such as heat intolerance, weight loss, diarrhoea and palpitations. Occasionally such antibodies block but do not activate the receptor, leading to symptoms associated with hypothyroidism. In addition, gradual protrusion of the eyes may occur, called Graves' ophthalmopathy, as may swelling of the front of the shins. Graves' disease can be diagnosed by the presence of pathognomonic features such as involvement of the eyes and shins, or isolation of autoantibodies, or by results of a radiolabelled uptake scan. Graves' disease is treated with anti-thyroid drugs such as propylthiouracil, which decrease the production of thyroid hormones, but hold a high rate of relapse. If there is no involvement of the eyes, then use of radioactive isotopes to ablate the gland may be considered. Surgical removal of the gland with subsequent thyroid hormone replacement may be considered, however this will not control symptoms associated with the eye or skin.
== Research uses == As an analog of L-phenylalanine, azidophenylalanine is incorporated into proteins during translation in place of phenylalanine. The azide group enables bioorthogonal reactions, such as copper-catalyzed or strain-promoted azide-alkyne cycloadditions, for protein modification. Azidophenylalanine is employed in metabolic labeling to detect nascent protein synthesis as a non-radioactive alternative to traditional methods. It facilitates site-specific protein labeling for microscopic imaging, purification, and FRET studies. Applications include photochemical control of fluorescent proteins, synthesis of ligands for metal complexation in EPR/NMR, and probing protein dynamics during folding or catalysis. It is incorporated using orthogonal tRNA/synthetase pairs in systems like E. coli.
Transabdominal incision: To realise an endoscopic TABA procedure (transabdominal breast augmentation), the plastic surgeon makes an incision at the navel that will allow tunneling superiorly (cutting upwards) under the abdominal skin — from the waist to the chest — in order to emplace the prosthetic breast into the bluntly-cut implant-pocket of the breast to be augmented, whilst the patient simultaneously undergoes an abdominoplasty procedure.
Sources: en.wikipedia.org
Stone-boiling and pit-baking were common techniques which involved heating large pebbles then transferring the hot stones into a perishable container to heat the water. This technology is typified in the Middle Palaeolithic example of the Abri Pataud hearths.
Starting in the United Kingdom in the 18th century, the discovery of steam power set off the Industrial Revolution, which saw wide-ranging technological discoveries, particularly in the areas of agriculture, manufacturing, mining, metallurgy, and transport, and the widespread application of the factory system. This was followed a century later by the Second Industrial Revolution, which led to rapid scientific discovery, standardization, and mass production. New technologies were developed, including sewage systems, electricity, light bulbs, electric motors, railroads, automobiles, and airplanes. These technological advances led to significant developments in medicine, chemistry, physics, and engineering. They were accompanied by consequential social change, with the introduction of skyscrapers accompanied by rapid urbanization. Communication improved with the invention of the telegraph, the telephone, the radio, and television. The 20th century brought a host of innovations. In physics, the discovery of nuclear fission in the Atomic Age led to both nuclear weapons and nuclear power. Analog computers were invented and asserted dominance in processing complex data. While the invention of vacuum tubes allowed for digital computing with computers like the ENIAC, their sheer size precluded widespread use until innovations in quantum physics allowed for the invention of the transistor in 1947, which significantly compacted computers and led the digital transition.
=== Superhydrophobicity === The simple adjustment of pore morphology and geometry of porous silicon also offers a convenient way to control its wetting behavior. Stable ultra- and superhydrophobic states on porous silicon can be fabricated and used in lab-on-a-chip, microfluidic devices for the improved surface-based bioanalysis.
== Motivation == Researcher Frederick Banting famously refused to put his name on the patent after discovering insulin in 1923. The original patent for insulin was later sold by his collaborators for just $1 to the University of Toronto in an effort to make it as available as possible. Despite this, for various reasons, there remains no generic version of insulin available in the US. Insulin remains controlled by a small number of large pharmaceutical companies and sold at prices unaffordable to many who rely on it to live, particularly those without insurance. This lack of availability has led to fatalities, such as Alec Smith, who died in 2017 due to lack of insulin. The Open Insulin Project is motivated by the urgent need to protect the health of those with diabetes regardless of their economic or employment status by developing low-cost methods for insulin production available for anyone to use.
Further development yielded β-lactamase-resistant penicillins, including flucloxacillin, dicloxacillin, and methicillin. These were significant for their activity against β-lactamase-producing bacterial species, but were ineffective against the MRSA strains. Another development of the line of penicillins was the antipseudomonal penicillins, such as carbenicillin, ticarcillin, and piperacillin, useful for their activity against Gram-negative bacteria. The usefulness of the β-lactam ring was such that related antibiotics, including the mecillinams, the carbapenems and, most important, the cephalosporins, still retain it at the centre of their structures.
Sources: en.wikipedia.org
Chloramphenicol has also been isolated from the moon snail Lunatia heros, although it has not been investigated whether the biosynthesis is carried out by the snail itself or by associated microorganisms. Also the biosynthetic gene cluster and pathway for chloroamphenicol was characterized from Streptomyces venezuelae ISP5230 (ATCC 17102). Currently the chloramphenicol biosynthetic gene cluster has 17 genes with assigned roles.
Castor oil is well known as a source of ricinoleic acid, a monounsaturated, 18-carbon fatty acid. Among fatty acids, ricinoleic acid is unusual in that it has a hydroxyl functional group. Because of this functional group, ricinoleic acid is more polar than most fatty acid. The alcohol group underpins the conversion of ricinoleic acid into sebacic acid and 2-octanol. Because of its ricinoleic acid content, castor oil is a valuable chemical in feedstocks, commanding a higher price than other seed oils. As an example, in July 2007, Indian castor oil sold for about USD $0.90 per kilogram ($0.41/lb), whereas U.S. soybean, sunflower, and canola oils sold for about $0.30 per kilogram ($0.14/lb).
The science of blood transfusion dates to the first decade of the 20th century, with the discovery of distinct blood types leading to the practice of mixing some blood from the donor and the receiver before the transfusion (an early form of cross-matching). In the early 19th century, British obstetrician James Blundell made efforts to treat hemorrhage by transfusion of human blood using a syringe. In 1818, after experiments with animals, he performed the first successful transfusion of human blood to treat postpartum hemorrhage at Guy's Hospital in London. Blundell used the patient's husband as a donor, and extracted four ounces of blood from his arm to transfuse into his wife. During the years 1825 and 1830, Blundell performed 10 transfusions, five of which were beneficial, and published his results. He also invented a number of instruments for the transfusion of blood. He made a substantial amount of money from this endeavour, roughly $2 million ($50 million real dollars). In 1840, Samuel Armstrong Lane, aided by Blundell, performed the first successful whole blood transfusion to treat haemophilia at St George's Hospital Medical School in London. However, early transfusions were risky and many resulted in the death of the patient. By the late 19th century, blood transfusion was regarded as a risky and dubious procedure, and was largely shunned by the medical establishment. Work to emulate James Blundell continued in Edinburgh. In 1845 the Edinburgh Journal described the successful transfusion of blood to a woman with severe uterine bleeding.
== Treatment == Standard intravenous preparations of potassium phosphate are available and are routinely used in malnourished people and people who consume excessive amounts of alcohol. Supplementation by mouth is also useful where no intravenous treatment are available. Historically one of the first demonstrations of this was in people in concentration camp who died soon after being re-fed: it was observed that those given milk (high in phosphate) had a higher survival rate than those who did not get milk. Monitoring parameters during correction with IV phosphate
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.